How Robin orchestrates multi-agent autonomous drug discovery in biology

Robin is a multi-agent workflow that coordinates three specialised AI agents developed by FutureHouse: Crow for literature search and synthesis, Falcon for experimental design and scientific evaluation, and Finch for experimental data analysis. A researcher inputs a disease name. Robin's agents then search the literature, generate therapeutic hypotheses, identify candidate molecules, design assays to test them, and analyse the resulting data when it comes back from the lab.

The proof-of-concept, published in Nature in May 2026, targeted dry age-related macular degeneration (dAMD). Robin proposed enhancing retinal pigment epithelium (RPE) phagocytosis as a therapeutic strategy, screened candidate molecules, and identified ripasudil, a Rho-kinase (ROCK) inhibitor already approved for glaucoma, as a novel candidate for dAMD. The entire process from conception to paper submission took 2.5 months. FutureHouse estimates a 200-fold reduction in researcher time compared to a conventional workflow.

Robin does not touch physical equipment. The experiments it designs are executed by human scientists or contract research organisations. The system is purely computational: it reads, reasons, proposes, and analyses, but it does not pipette, centrifuge, or incubate.

How BioSkepsis retrieves and reasons over biomedical literature for researchers

BioSkepsis retrieval is weighted by Gene Ontology terms, MeSH descriptors, gene symbols, and pathway relationships. A query about AMPK activation and its downstream effects on hepatic lipogenesis returns papers linked by the biological concepts involved, not just papers whose abstracts contain matching keywords. This biology-native retrieval layer is what separates BioSkepsis from both general-purpose LLMs and autonomous discovery systems that treat biomedical papers as undifferentiated text for hypothesis mining.

Answers are grounded in full text including methods, controls, and supplementary data. Every claim links back to the exact passage in the retrieved paper. When evidence is insufficient, BioSkepsis declines to answer rather than generating a plausible-sounding response. The research landscape graph classifies papers by structural role (Foundational, Hub, Bridge, and Novel) and draws on Semantic Scholar's 214M+ corpus for landscape expansion.

BioSkepsis also performs citation verification: a seven-step pipeline (Steps A through G) that audits whether cited papers in an existing document actually support the claims they are attached to. This is a forensic capability; it checks the integrity of literature use, not just its availability.

The EFEVRE ecosystem: physical execution, documentation, and interpretation in one loop

BioSkepsis is one of three products built by EFEVRE TECH LTD. The other two address problems that Robin does not attempt to solve.

AMGEL (AutoMated GEneral Laboratory) is a patent-pending robotic platform that automates all mainstream wet-bench procedures on one device: pipetting, centrifugation, heating/cooling, magnetic bead isolation, cold storage, and PCR. It runs 860+ pre-set protocols with 24/7 unattended operation. AMGEL physically executes the experiments that tools like Robin can only propose on paper.

VITALE (Versatile Integrated Technology Advancing Life-Science Exploration) is the software layer that records every step, parameter, timestamp, and result during AMGEL operation. Its Protocol Designer, Personal Labbook, Scheduling Calendar, and Protocol Library with community scoring ensure that no experimental detail goes undocumented. VITALE addresses the documentation pillar of the reproducibility crisis: even when experiments are performed correctly, poor reporting in publications makes replication structurally impossible.

Together, the three products form a closed loop: AMGEL removes human error from execution, VITALE removes human error from documentation, and BioSkepsis removes human bias from interpretation. Robin's architecture does not include either a physical execution layer or a documentation integrity layer.

Feature comparison: BioSkepsis (EFEVRE ecosystem) vs Robin (FutureHouse/Edison)

Where Robin leads: autonomous discovery and experimental data analysis in drug development

Robin's primary advantage is its end-to-end autonomy. A researcher provides a disease name; Robin returns validated drug candidates, proposed assays, and analysed experimental data. The system orchestrates multiple specialised agents in a continuous workflow that compresses months of manual work into days. In the dAMD proof-of-concept, the entire intellectual pipeline from literature review through RNA-sequencing analysis was completed without manual intervention in the computational steps.

Finch, the data-analysis agent, represents a capability BioSkepsis does not offer. Finch processes raw experimental datasets: gene expression profiles, screening results, flow cytometry data, and omics outputs. It identifies statistically significant patterns and proposes biological hypotheses directly from the data, linking findings back to literature where possible.

Edison Scientific's next-generation system, Kosmos, extends this further, reportedly processing 1,500 papers and 42,000 lines of analysis code in a single run, performing the equivalent of six months of postdoctoral research time per session. The trajectory is clear: increasingly autonomous computational science, with the human scientist directing the process and validating the outputs.

Where BioSkepsis leads: citation integrity, reproducibility, and the physical research layer

BioSkepsis occupies territory Robin does not enter. Citation verification, the seven-step audit pipeline that checks whether cited papers actually support the claims they are attached to, has no equivalent in the FutureHouse agent stack. Robin's Crow and Falcon agents synthesise literature to generate new hypotheses; they do not audit the integrity of citation use in existing publications. For researchers, reviewers, and editors concerned with the accuracy of the scientific record, this is a meaningful gap.

The research landscape graph, with its classification of papers into Foundational, Hub, Bridge, and Novel roles via citation network analysis, provides structural understanding of a field that Robin's agents do not surface. A researcher mapping the state of a sub-discipline, identifying which seminal papers anchor the field and which bridge papers connect separate domains, needs this kind of analysis. Robin's agents read papers to extract hypotheses; BioSkepsis maps the relationships between papers to reveal field structure.

The EFEVRE ecosystem's physical layer is the most decisive differentiator. AMGEL runs 860+ laboratory protocols autonomously, 24 hours a day. VITALE records every parameter. No AI-only platform, including Robin, addresses the reproducibility crisis at the bench. Robin proposes experiments; the EFEVRE ecosystem executes, documents, and interprets them.

Where BioSkepsis and Robin overlap, and how they complement each other in biomedical research

The overlap is in literature synthesis and hypothesis generation. Both BioSkepsis and Robin's Crow/Falcon agents read biomedical papers and produce citation-grounded outputs. A researcher querying either system about a signalling pathway will get a synthesised answer with references. On this axis, the two tools are comparable in intent if not in architecture.

The difference in retrieval matters. BioSkepsis uses a biology-native knowledge graph weighted by Gene Ontology, MeSH, and gene symbols. Robin's agents use LLM-driven queries against scientific literature. For queries where biological specificity determines relevance (e.g., distinguishing papers about AMPK activation via LKB1 from those about AMPK activation via CaMKK2), domain-specific retrieval outperforms keyword and embedding approaches.

The complementary workflow is clear. Robin identifies a therapeutic candidate for a disease. AMGEL executes the proposed assays with full parameter control. VITALE records every experimental step. BioSkepsis verifies that the resulting publication cites the literature accurately and completely. Each system handles a distinct phase; none duplicates another's core job.

Who should use which tool in biomedical and life-science research

Frequently asked questions